If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
154
results.
Updated on
02/05/2025 [06:51:00]
Absstract of: AU2023361218A1
The present invention relates to compounds of formula (I). The invention also extends to micro- or nanoparticles comprising a compound of formula (I). For instance, compounds of formula (I) can be used to produce stable lipid nanoparticles (LNPs). The LNPs have high encapsulation efficiency and can be used to deliver a therapeuticor prophylactic agent to a patient.
Absstract of: AU2023347284A1
Provided here are novel engineered and isolated signal peptide sequences and compositions comprising these. Also provided are compositions and methods of using these signal peptides to enable secretion of heterologous polypeptides for therapeutic, diagnostic, and commercial value.
Absstract of: AU2025202623A1
The present invention provides a pharmaceutical composition comprising a peroxisome proliferator activated receptor (PPAR) modulator and an polymeric nanocarrier component, wherein the polymeric nanocarrier component is capable of solubilising the PPAR modulator in an aqueous medium and, wherein in the polymeric nanocarrier component is a micelle forming non-ionic surfactant. Uses of the same in therapy are also provided.
Absstract of: AU2023365462A1
It is an object of the present invention to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem/progenitor cell or mesenchymal stem cells, and a method of delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule, wherein the lipid nanoparticle comprises an ionizable lipid, and the targeting molecule specifically binds to a marker of hematopoietic stem / progenitor cells or mesenchymal stem cells.
Absstract of: AU2023360051A1
The invention relates to oligonucleotides that inhibit Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8), or potentiate TLR8, and uses thereof.
Absstract of: EP4545561A1
The present invention relates to a novel nanobody (Nb) and a nanobody-drug conjugate (NDC) targeting CD73, a method for preparing same, and use thereof. The monoclonal nanobody and the corresponding NDC can efficiently bind to isolated CD73, various tumor cells and CD73 on the surface of an immune cell with high specificity and block the catalytic activity of CD73 enzymes, exhibiting high affinity, low immunogenicity, and a significant anti-tumor effect.
Absstract of: AU2022463987A1
The present invention relates to combination therapies for treating cancer, optionally chemotherapy-resistant cancers, in a subject. The combination therapies comprise (a) an antibody or antigen-binding portion thereof that specifically binds to CD40, and (b) chemotherapy. The invention also relates to pharmaceutical compositions, kits and methods of using such therapies.
Absstract of: AU2023288520A1
Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.
Absstract of: AU2023288487A1
The disclosure relates to ionizable lipids and compositions comprising the ionizable lipids. Lipid-nanoparticle compositions comprised of an ionizable lipid, optionally in combination with other lipid components such as helper lipids, stabilization lipids and structural lipids, and a therapeutic agent, such as a nucleic acid, for delivery to mammalian cells or organs are described.
Absstract of: WO2023247047A1
The present invention refers to a peptide, comprising or consisting of SEQ ID NO: 1 (CAYMTMKIRN), for use as a medicament, preferably in the prevention and/or treatment of cardiac damage arising after ischemia followed by reperfusion, or in the prevention and/or treatment of the inflammatory response following acute myocardial infarction. In a preferred embodiment, the peptide is conjugated with a nanoparticle.
Absstract of: CN119899835A
本申请公开了一种高效表达GBA1的mRNA及其应用。本申请高效表达GBA1的mRNA由5’端至3’端依序包括5’甲基化帽子、5’UTR、目的基因序列、3’UTR和polyA尾巴；其中，目的基因序列为编码GBA1蛋白或GBA1突变蛋白的序列。本申请高效表达GBA1的mRNA，通过修改mRNA不同元件来获得更稳定、表达效率更高的GBA1mRNA。
Absstract of: CN119896651A
本发明属于生物技术技术领域，具体涉及一种基于磷酸钙介导的外泌体药物递送系统，并进一步公开其制备方法与应用。本发明所述基于磷酸钙介导的外泌体药物递送系统，通过Ca2+和磷酸盐构建形成磷酸钙介导的外泌体递送体系，通过氯化钙转染miRNA后可以将核酸药物载入到外泌体中，外泌体中miRNA的含量显著提高，进而借助于外泌体的递送性能将药物运输，有效提高了药物的载药效率和递送效率，具有装载效率高的优势。
Absstract of: CN119899218A
本文描述了作为光热转导剂的环金属化铁(II)络合物。所公开的络合物表现出高结构稳健性和在近红外(NIR)和可见光区域的显著吸收。所描述的络合物可以自组装以形成金属超分子粒子，其具有优异的光热性能并可以通过EPR效应靶向肿瘤。例如，本文公开的Fe NP具有强的近红外(NIR)吸光度，在近红外(例如，808nm)激光照射下具有至少30％(例如约60％)的高光热转换效率和/或优异的光热稳定性。Fe NP可以用包衣剂(例如牛血清白蛋白)包衣以形成包衣的Fe NP，这可以进一步增强金属超分子粒子在体内的肿瘤积累和生物相容性。Fe NP的优异光热性能使其能够解决与大多数现有光热材料相关的光热转换效率低的问题。
Absstract of: CN119896731A
本发明属于光热材料制备技术领域，具体涉及一种液态金属纳米颗粒光热材料的制备方法，包括：步骤1、配制海藻酸钠水溶液；步骤2、在海藻酸钠水溶液中加入镓基液态金属，先通过搅拌混合，再通过超声处理充分混合；步骤3、干燥后得到生成物。本发明的制备过程是在常规环境下制备，对环境的要求低。另外，本发明制备的纳米颗粒具有稳定性好、光热性能佳、制备方法简单、形成速率快、易控制的特点，可制备具有高效光热能力的材料。综合以上有益效果，本发明在光热材料制备技术领域具有良好的应用前景。
Absstract of: CN119899206A
本发明公开了一种基于脐带间充质干细胞囊泡负载I型光敏前药的纳米囊泡及其制备方法与应用，其包括来源于人脐间充质干细胞的囊泡及其负载的所述I型光敏前药。本发明的优点包括：纳米囊泡EVs@NBS‑PB的I型光敏前药可与糖尿病慢性伤口微环境中高水平的H2O2响应释放I型光敏剂，再通过激光激发后产生PDT效应释放活性氧达到抗菌的目的，实现对糖尿病慢性创面的靶向抗感染作用，结合来源于人脐间充质干细胞的囊泡调节伤口微环境来协同治疗慢性创面；干细胞囊泡不仅能够提高光敏前药的生物相容性，同时还具有促细胞增殖、迁移及血管生成的作用；用水凝胶微针贴片装载给药的方式不仅具有高药物递送效率和微创性，同时也能提高患者的依从性。
Absstract of: CN119868305A
本发明提供一种调控缺血微环境的工程化血小板膜纳米载体及其制备方法。所述工程化血小板膜纳米载体由纳米颗粒(DY)和形成于所述纳米颗粒(DY)表面的血小板膜组成，其中，所述纳米颗粒(DY)通过长链分子DSPE‑PEG2000‑Arg‑TK‑CY‑09自组装形成，TK表示ROS响应材料硫缩酮键，CY‑09表示抑制NLRP3炎症小体活化及组装的抗炎药物CY‑09，Arg表示产生NO的L‑Arg，DSPE‑PEG2000表示两亲性聚合物。本发明所提供的工程化血小板膜纳米载体(DY@PM)具有较高的稳定性和生物安全性，可靶向病灶部位，多靶点协同调控缺血微环境，在生物医学领域具有广阔的应用前景。
Absstract of: CN119868304A
本发明属于纳米技术领域，具体公开了一种具有抗菌功能的含铁脂质纳米粒IO‑LNPs的制备方法和应用。以油酸铁、大豆卵磷脂和DSPE‑MPEG2000为原料，通过梯度溶剂扩散法合成了具有抗菌功能的含铁脂质纳米粒(IO‑LNPs)，其能诱导细菌铁死亡效应，具有良好的抗菌活性，能够有效杀灭革兰氏阳性(S.aureus，)和阴性(E.coli)菌株，而且对S.aureus和E.coli具有良好的生物膜预防和破坏能力。本发明制备的具有抗菌功能的含铁脂质纳米粒IO‑LNPs在生理条件下表现出较高的稳定性和生物相容性，在抗菌性能上具有优异的效果，是对抗细菌感染和促进伤口愈合的安全高效的药剂。
Absstract of: CN119876277A
本发明提供了一种脂质纳米颗粒及其应用。本申请对脂质材料配方的比例、最优细胞培养及编辑体系、编辑系统Cas9mRNA：sgRNA比例、Cas9mRNA设计优化进行一系列探索，摸索出适合于针对人造血干细胞转染及编辑的系统，本申请在节约成本的同时，可完全替代目前已有的市面转染试剂不能有效转染原代细胞的问题，实现原代细胞内编辑效率的显著提高，进而能在体内得到很好的治疗效果。
Absstract of: CN119874742A
本发明公开了一种噻吩取代的氮杂氟硼二吡咯化合物、化合物的纳米颗粒及它们的制备方法和应用。本发明设计并合成的噻吩取代的氮杂氟硼二吡咯化合物，噻吩基团的引入可以使氮杂氟硼二吡咯的吸收光谱显著红移，成功红移至810nm近红外区域，更有利于其在生物体内以及光热治疗方面的应用。以该化合物为内核制备的纳米颗粒在局部腹腔给药后可以有效地分布到内脏脂肪组织，选择性地靶向内脏脂肪组织，具有良好的生物相容性和较高的光热转换效率，可以通过调节其浓度和808nm激光功率实现对温度的调控，可用于光热治疗肥胖。
Absstract of: CN119874811A
本发明涉及一种用于抑制新生血管生成的自组装多肽及其制备方法和应用，所述自组装多肽包括疏水单元、组装单元、特异性靶向Tie2受体的多肽和特异性靶向VEGFR2受体的多肽。本发明提供的自组装多肽同时靶向Tie2受体和VEGFR2受体，特异性靶向血管内皮细胞，在亲疏水作用下自组装形成纳米颗粒，经过配受体相互作用后，由纳米颗粒转变为纳米纤维，阻碍VEGF结合VEGFR2和Ang2结合Tie2，实现在新生血管病灶区域的快速富集，抑制内皮细胞迁移，进而抑制血管的生成。
Absstract of: CN119868303A
本申请公开了一种雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料及其应用，属于纳米材料合成领域。该雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料为纳米级颗粒，呈方块状结构，包括方块状普鲁士蓝纳米颗粒和包覆在普鲁士蓝纳米颗粒外的雷公藤外泌体样纳米囊泡。通过将雷公藤外泌体纳米囊泡PELNVs加入到普鲁士蓝纳米颗粒溶液中混合，将混合后的体系采用物理挤压使其反复通过聚碳酸酯膜制备得到。所得雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料具备优异的光热转换性能和抗氧化性能，且溶血率保持极低水平，细胞毒性低，用于类风湿关节炎光热治疗，具有优异的光热治疗能力，生物安全性好，应用前景广泛。
Absstract of: CN119874553A
本申请公开了一种化合物，结构式如式(I)所示，以及其药学上可接受的盐或其立体异构体，本申请还公开了一种包含上述化合物或其药学上可接受的盐或其立体异构体的纳米颗粒组合物，本申请的纳米颗粒可以高效递送药物、疫苗至细胞内，发挥药物、疫苗的治疗或预防目的。#imgabs0#
Absstract of: CN119868544A
本发明涉及生物医药技术领域，尤其涉及一种白蛋白维替泊芬纳米粒的制备方法及其应用。白蛋白维替泊芬纳米粒在治疗肿瘤中的应用；白蛋白维替泊芬纳米粒的制备方法，步骤如下：将白蛋白聚合物水溶液与维替泊芬高速搅拌反应，并通过100kDa超滤管纯化。本发明提供的一种白蛋白维替泊芬纳米粒的制备方法及其应用，制得的白蛋白维替泊芬纳米粒，其仅能明显增加穿过细胞的药物量，进入细胞后维替泊芬的光动力效应还具有抗肿瘤效果。
Absstract of: MX2021004357A
The present invention provides: a method which is for the activation and/or proliferation of T cells and includes a step for bringing a T cell-containing cell population into contact with a nucleic acid delivery carrier having a surface to which at least one T cell-activating ligand is added; a method which is for delivering a nucleic acid into a T cell and includes a step for bringing a T cell-containing cell population into contact with (a) a nucleic acid delivery carrier that has a surface to which at least one T cell-activating ligand is added and that contains a nucleic acid therein, or (b) both of at least one T cell-activating ligand and a nucleic acid delivery carrier that has a surface to which a T cell-activating ligand is not added and that contains a nucleic acid therein; and a method for producing a medicament that contains T cells.
Absstract of: CN119876208A
本发明公开了PEDV与TGEV环状RNA二联苗的创制与应用。本发明提供的疫苗组合物由PEDV环状RNA疫苗和TGEV环状RNA疫苗组成，其可以同时防治猪流行性腹泻病毒、猪传染性胃肠炎病毒两种传染病，与单苗相比，二联疫苗组合物没有产生免疫干扰现象，疫苗免疫效果没有下降，可以避免多次接种免疫出现的不良反应，具有广泛的应用价值。
Absstract of: CN119868272A
本发明公开了一种兽用复方黄芪多糖注射液及其生产工艺，属于兽用医药配制品技术领域，包括如下步骤：将黄芪多糖溶解后与复合纳米颗粒复合得到黄芪多糖负载粉末；将表面活性剂和无水乙醇加入液体石蜡中，将分散液边搅拌边加入反应釜中，然后搅拌得到复方黄芪多糖注射液；本发明的生产工艺通过将环糊精制备成载体吸附和封装黄芪多糖，并利用环糊精载体的吸附能力与聚乳酸形成核壳结构，将包覆有纳米硒的聚乳酸负载在环糊精载体内，既阻止了纳米硒在注射液中的团聚，也使黄芪多糖分散性提高，通过将复合纳米颗粒制备成乳液，提高复合纳米颗粒的分散性，乳液形态的注射液更容易被动物吸收，使纳米硒与黄芪多糖产生协同作用，提高动物的抵抗力。
Absstract of: CN119868526A
本发明属于疫苗制备领域，具体涉及一种基于幽门螺杆菌外膜囊泡的纳米疫苗及其制备方法与应用。本发明以幽门螺杆菌的OMV和LPS为抗原和佐剂，以DMON为载体，然后利用静电相互作用使DMON吸附LPS小分子，再利用脂质体挤出器将幽门螺杆菌OMV均匀包裹在DMON纳米材料表面，得到基于幽门螺杆菌外膜囊泡的纳米疫苗。本发明通过体内外试验证明该纳米疫苗能够被巨噬细胞摄取，促进巨噬细胞的吞噬能力，显著提高巨噬细胞分泌各种免疫细胞因子的水平，能在小鼠体内诱导高水平的抗原特异性体液免疫、黏膜免疫以及Th1/Th2/Th17型细胞免疫应答。
Absstract of: CN119868302A
本发明涉及生物医用材料领域，公开了一种含有抗氧化剂和siRNA的纳米复合物及其制备方法和应用。其制备方法包括：以含有氨基的抗氧化剂和含有苯硼酸结构的化合物为原料，在鎓盐类酰胺化偶联剂催化下得到苯硼酸键修饰的抗氧化剂；将苯硼酸键修饰的抗氧化剂和含有邻二酚结构的脂质在有机溶剂中反应，得到抗氧化剂偶联的脂质；将该脂质和阳离子脂质混合，溶于低沸点有机溶剂，再加入含有siRNA MMP9的DEPC水溶液，超声、减压浓缩，得到含有抗氧化剂和siRNA的纳米复合物。本发明所制备的纳米复合物仅使用两种不同功能的脂质通过静电作用，即可实现对siRNA的有效负载，具有制备方法简单、有效成分明确、生物相容性良好等优点等。
Absstract of: CN119874554A
本申请公开了一种化合物，结构式如式(I)所示，以及其药学上可接受的盐或其立体异构体，本申请还公开了一种包含上述化合物或其药学上可接受的盐或其立体异构体的纳米颗粒组合物，本申请的纳米颗粒可以高效递送药物、疫苗至细胞内，发挥药物、疫苗的治疗或预防目的。#imgabs0#
Absstract of: WO2023244526A1
A monolithic implantable device for delivery of an antibody is provided. The implantable device comprises a polymer matrix within which is dispersed a pharmaceutical formulation that includes one or more therapeutic agents and optionally, one or more excipients. The therapeutic agents contain an antibody and the polymer matrix contains a hydrophobic polymer. Within a time period of 35 days, the device exhibits a cumulative weight-based release ratio of the antibody of from about 20% to about 60%.
Absstract of: CN119868308A
本发明属于生物医药技术领域，公开了一种治疗缺血性脑卒中的重组脂质纳米粒及其制备方法和应用。本发明以芹菜籽(Celery seeds，CS)为原材料采用有机溶剂提取法提取脂质，再通过乙醇注入法成功制备芹菜籽重组脂质纳米粒(CS‑rLNPs)。本发明公开的提取工艺简单，原料易得，制备的纳米药物CS‑rLNPs具有生物安全性、稳定性好等优点；经体内外实验表明，CS‑rLNPs能有效穿透血脑屏障和优先分布到缺血半暗区，并能够与脑缺血区域的神经元结合，表现出独特的神经元靶向性；除此之外，该纳米粒对缺血性脑卒中的治疗具有实用价值。因此，本发明的重组脂质纳米粒具有良好的临床应用价值和前景。
Absstract of: CN119874737A
本发明公开了一种两亲性氮杂氟硼荧类荧光染料及其制备方法和应用；通过在氮杂氟硼荧类荧光结构中引入两个四甘醇作为亲水结构，引入四个C8或者C18的烷基链作为疏水基元，通过慢加水或者闪沉方式可以组装得到纳米粒子，纳米片以及支化纳米棒结构，并且这些纳米结构在808nm处有非常强的吸收，具有优异的光热转换效果，可以用于肿瘤的光热治疗。
Absstract of: CN119874723A
本发明提出了一种近红外二区AIE探针与光激活治疗膀胱癌的纳米材料，属于材料化学技术领域，针对光热疗法对膀胱癌治疗效果不佳的问题，本发明设计了一种能够在近红外二区进行高效光热转化的AIE探针，并在其基础上将AIE探针与热敏NO供体共混，将近红外光诱导光热转换释放NO；用两亲性聚合物封装后再修饰细胞膜表面PMCA钙离子通道阻断肽和肿瘤表面FGFR1受体靶向肽，细胞膜表面PMCA钙离子通道阻断肽与热敏NO供体释放的NO共同作用，通过内源性与外源性联合调节钙离子通路，造成肿瘤钙超载，诱导肿瘤细胞凋亡；表面修饰的肿瘤表面FGFR1受体靶向肽可实现该纳米材料在肿瘤部位高效富集，提高治疗效果。本发明所提供的材料为膀胱癌治疗提供了新的思路。
Absstract of: CN119868306A
本发明公开了一种负载过氧化铜的自佐剂化纳米药物及制备方法与应用，制备方法包括：制备酰肼化透明质酸；将酰肼化透明质酸经配位和静电吸附作用修饰于纳米氮化铝表面，得到透明质酸化纳米氮化铝；将透明质酸化纳米氮化铝通过铜‑酰肼配位/矿化反应原位制备负载过氧化铜的自佐剂化纳米药物。该纳米药物能响应肿瘤微环境发生分解，进而消耗谷胱甘肽、自供过氧化氢、自生成纳米佐剂、中和肿瘤酸性，可经氨毒性和类芬顿催化活性实现抗肿瘤治疗应用。
Absstract of: TW202440536A
The present application discloses compounds of formula (I), as well as salts and stereoisomers thereof, wherein the variables are as defined in the specification. The present application also discloses nanoparticle compositions comprising the compounds or salts or stereoisomers thereof, and the use of the nanoparticle compositions for delivering active agents.
Absstract of: CN119868309A
一种同时递送光敏剂和靶向抗体的纳米颗粒及其制备方法和应用。本发明提供的纳米颗粒，含有光敏剂、一氧化氮前体、siRNA、和巨噬细胞膜，所述光敏剂为焦脱美叶绿素a分子，所述siRNA为siPD‑L1，所述一氧化氮前体为九聚精氨酸。本发明提供的靶向纳米颗粒可实现光敏剂和siRNA的高效递送。本发明将精氨酸与焦脱镁叶绿酸a按1:1共价连接，制备纳米粒后，通过静电吸附原理负载带负电的siPD‑L1，通过包裹M1巨噬细胞膜囊泡，降低纳米颗粒表面电荷同时提高纳米颗粒的肿瘤靶向能力。在650nm激光照射下可实现光动力和抗PD‑L1免疫联合治疗恶性肿瘤。
Absstract of: TW202434543A
The present application discloses a compound with a structural formula as shown in formula (I), and a salt or an isomer thereof. The present application also discloses a nanoparticle composition containing the compound and a salt or an isomer thereof. The nanoparticle composition of the present application can efficiently deliver drugs into cells and exert therapeutic or prophylactic effects of drugs.
Absstract of: WO2024044178A1
The present disclosure relates generally to lipid nanoparticle compositions comprising a nucleic acid, an ionizable polymer, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid. Further, the present disclosure relates generally to methods of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition described herein.
Absstract of: AU2023337954A1
The present disclosure provides delivery vehicle compositions comprising hydroxyalkyl-capped cationic peptoids, such as 2-aminopropane-1,3-diol-capped cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.
Absstract of: CN119868307A
本发明涉及生物医用领域，具体提供一种杂化纳米颗粒及其制备方法、用途，旨在解决循环血液中的乳酸过多对败血症治疗过程的不良影响。为此目的，本发明的杂化纳米颗粒的制备方法包括：制备聚丙烯胺盐酸盐改性的中空介孔二氧化锰；合成柱5芳烃功能化透明质酸；在所述聚丙烯胺盐酸盐改性的中空介孔二氧化锰上负载乳酸氧化酶，得到中间体；在所述中间体的表面通过静电相互作用包被所述柱5芳烃功能化透明质酸，得到杂化纳米颗粒。本发明提供的杂化纳米颗粒制备简便、成本低廉，可广泛应用于材料学、生物学、医学等领域，具有良好的生物相容性；能够以双管齐下的乳酸清除方式有效下调循环血液乳酸浓度，有望在体内实验中有效控制LPS诱导的败血症进程。
Absstract of: CN119868310A
本发明公开了一种包埋γ‑氨基丁酸的木薯淀粉‑β‑环糊精纳米微粒的制备方法和应用，所述的制备方法包括如下步骤：步骤一）、用木薯淀粉悬浮液和β‑环糊精制备纳米微粒，再制成溶液；步骤二）、制备γ‑氨基丁酸溶液，制备得到的γ‑氨基丁酸溶液与步骤一）的纳米微粒溶液混合。本发明的γ‑氨基丁酸的木薯淀粉‑β‑环糊精纳米微粒可以提高γ‑氨基丁酸的稳定性，进一步改善γ‑氨基丁酸提高睡眠质量的效果，在医药生产中具有实际应用价值。
Absstract of: CN119874800A
本发明涉及药物输送领域，具体涉及一种脂质化合物、包含该脂质化合物的药物组合物及其制剂和应用。将本发明提供的脂质化合物应用于脂质纳米颗粒系统中，可以将传统的四组分脂质纳米颗粒变为三组分脂质纳米颗粒，提高脂质纳米颗粒药物递送系统的制备效率，并同时具有较好的安全性。
Absstract of: WO2025085425A1
A non-cationic nanoparticle composition comprising an albumin-coated nanoparticle, which comprises a nucleic acid bound to a polyphenol; a method of preparation; and use thereof in the treatment or inhibition of onset of cancer and other diseases.
Absstract of: WO2025085909A1
Disclosed herein are nanoparticle immunoadjuvant complexes and nucleic acid molecules encoding the same. Also disclosed herein is a method of treating or preventing a disease or disorder associated with an antigen presented on n nanoparticle immunoadjuvant complex in a subject in need thereof, by administering the antigen presenting nanoparticle immunoadjuvant complex, or encoding nucleic acid molecules, to the subject.
Absstract of: WO2025085865A1
Provided herein are co-assembling peptides which may form granules under stimulating conditions. Also provided herein are granules comprising RNA-guided nucleases which are capable of modifying DNA, for example, in the presence of a guide RNA. Further provided herein are methods of making each of the co-assembling peptides and granules thereof.
Absstract of: WO2025085796A1
The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target DLL3 and cells comprising such DLL3-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the DLL3-targeted antigen-recognizing receptors for treatment.
Absstract of: WO2025085507A2
The present invention provides multi-functional (e.g., repelling biofilms, promoting formation of minerals, and having anti-infection properties) compositions and methods of use thereof. In various embodiments, the present invention also provides method for promoting bone growth, promoting cell adhesion, promoting cell expression, promoting anti-infection effect (e.g., promoting anti-bacterial effect, promoting anti-fungal effect, promoting anti-viral effect, etc.), promoting anti-inflammatory effect, preventing or treating diseases or disorders, or any combination thereof in a subject in need thereof.
Absstract of: WO2025085275A1
The present disclosure provides compositions and methods for increasing mitochondrial function or decreasing cellular oxidative stress. The present disclosure further provides nanomaterial structures comprising high atomic vacancy concentrations. Aspects of the disclosure further relate to methods for treating diseases or disorders associated with decreased mitochondrial function or increased cellular oxidative stress.
Absstract of: WO2025084317A1
The purpose of the invention described herein is to provide a compound having a novel chemical structure that is usable for lipid nanoparticles. Disclosed are a compound represented by formula (I) (in the formula, R1 and R2 are each independently a C10-24 chain hydrocarbon group, R3 is a C1-22 chain hydrocarbon group) and lipid nanoparticles containing the compound.
Absstract of: WO2025084854A1
When a biological material sensitive to an external reaction is incorporated during hydrogel production, physical stimulation or chemical stimulation applied in conventional hydrogel production methods requires a sophisticated process and can affect the activity and structure of particles in the hydrogel. On the other hand, a hydrogel using an aqueous-two phase system and a method for producing same provided by the present invention can simultaneously achieve hydrogel formation and the encapsulation of desired nanoparticles in the hydrogel. The present invention has succeeded in simply concentrating desired nanoparticles in a hydrogel with a high yield. In addition, the present invention relates to a hydrogel using an aqueous-two phase system and a method for producing same, wherein concentration and hydrogel formation are simultaneously performed, and thus the time for producing the hydrogel is reduced and the cost is significantly reduced.
Absstract of: WO2025083657A1
The present invention relates to a novel lipid compound for tissue-specific delivery and a lipid nanoparticle (LNP) including same. The lipid nanoparticle includes, as a component, a lipid compound modified such that an active substance therein is selectively delivered into cells of a specific tissue such as lymph nodes, the spleen, the retina, cancer, the brain, the liver, and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effects. These tissue-specific, non-viral LNP carriers can be effectively utilized for the prevention of infectious diseases and the treatment of rare and intractable (hereditary) diseases (macular degeneration, diabetic retinopathy, hereditary retinal degeneration, cancer, brain diseases, liver diseases, and etc.), where targeted and selective delivery within the body is crucial.
Absstract of: WO2025082397A1
The present application discloses a compound having a structural formula as shown in formula (I), and a salt and isomer thereof. The present application also discloses a nanoparticle composition comprising the compound or the salt or isomer thereof. The nanoparticle of the present application can efficiently deliver an active ingredient into a cell to achieve the purpose of treatment or prevention.
Absstract of: WO2025082447A1
Provided are a nanobody targeting 5T4 and a use thereof. Specifically, provided are an anti-5T4 nanobody, and a long-acting anti-5T4 nanobody formed by linking the anti-5T4 nanobody with an anti-serum-albumin nanobody in tandem. Furthermore, the antibody can be used for preparing an antibody-drug conjugate and constructing a chimeric antigen receptor and an engineered immune cell expressing the chimeric antigen receptor. The antibody, the antibody-drug conjugate, and the engineered immune cell can be used for preparing a drug for treating and/or preventing diseases or disorders associated with 5T4, such as solid tumors and malignant hemopathies.
Absstract of: WO2025081381A1
Nanoparticles capable of realizing controlled release of carbon monoxide, and a preparation method therefor and the use thereof. The nanoparticles capable of realizing controlled release of carbon monoxide comprise triiron dodecarbonyl and Croc-PEG that coats triiron dodecarbonyl, wherein Croc-PEG is a condensation product of Croc and MPEG-NH2. The nanoparticles capable of realizing controlled release of carbon monoxide can effectively improve the loading capacity of carbon monoxide, thereby achieving controlled release of carbon monoxide and high-efficiency low-toxicity CO gas therapy.
Absstract of: AU2023256601A1
Provided herein are compositions and methods related to tRNA therapeutics for treating vision loss and blindness.
Absstract of: AU2023257167A1
The present invention provides a pharmaceutical composition for treating obesity, the composition including: one or more viruses selected from the group consisting of yellow fever virus, herpes zoster virus, and rubella virus; or a genetic material coding for a protein derived from these viruses. Preferably, the pharmaceutical composition is a vaccine composition. The composition provides a reduction in target tissues, preferably tissues containing adipocytes, or an effect that leads to the death of adipocytes.
Absstract of: CN119403545A
The present invention relates to a solid composition obtainable by freeze-drying an aqueous composition comprising rilpivirine or a pharmaceutically acceptable salt thereof and optionally a hyaluronidase. The invention also relates to a reconstituted aqueous composition obtainable by reconstituting a solid composition of the invention, a process for preparing a solid composition of the invention and the use of the reconstituted aqueous composition in the treatment or prevention of HIV infection in a subject.
Absstract of: WO2025082973A1
The present invention relates to ionizable lipids for use in lipid nanoparticles, lipid nanoparticle formulations comprising these ionizable lipids, alone or in combination with other lipids and/or polymers. The lipid nanoparticles formulations may be formulated with nucleic acids for their delivery to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration.
Absstract of: TW202432572A
The present application relates to the field of biotechnology, specifically to an mRNA vaccine for treating HPV infection related diseases by inducing HPV antigen-specific immune responses.
Absstract of: US2025127720A1
Disclosed herein is a method for the delivery of prenatal therapeutics, enzyme replacement therapy, or gene therapy to a fetus in need thereof. The method comprises introducing ionizable lipid nanoparticles (LNPs) nanoparticles comprising a therapeutic mRNA composition into the circulation of the fetus in need of treatment such that the ionizable LNPs deliver the therapeutic mRNA composition.
Absstract of: AU2025202461A1
Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAIl or DNAH5.
Absstract of: US2025127935A1
Prostate-specific membrane antigen (PSMA) targeted compounds having formula (I), nanoclusters formed thereof, pharmaceutical compositions comprising a plurality of these compounds, and methods for treating and detecting cancers in a subject are described herein.
Absstract of: US2025127925A1
Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.
Absstract of: US2025127887A1
The present disclosure relates to a vaccine comprising an amphiphile having the formula S-B-U-H and at least one peptide antigen conjugate having the formula selected from S-E1-A-E2-U-H and H-U-E1-A-E2-S, wherein the amphiphile and/or the at least one peptide antigen conjugate comprises a dendron amplifier. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, an infectious disease, a cardiovascular disease, or a neurodegenerative disease.
Absstract of: US2025127921A1
Provided herein are self-assembled nanoparticles (NPs), pharmaceutical compositions containing such NPs and methods of using such NPs. The NPs comprise an amphiphilic copolymer and a ribonucleoprotein (RNP), and optionally ssODN, wherein: the amphiphilic copolymer is a water-soluble block copolymer comprising a poly(C2-3 alkylene glycol) block and an acrylic block comprising a poly(acrylate), poly(methacrylate) or poly(acrylate/methacrylate) block; the acrylic block comprise ester side chains bearing substituted or unsubstituted alkylamine groups; and the RNP, ssODN, and the acrylic block of the amphiphilic copolymer form a core of the self-assembled nanoparticle, and the poly(ethylene glycol) block of the amphiphilic copolymer forms the exterior of the self-assembled nanoparticle.
Absstract of: US2025127761A1
A method of inhibiting viral replication of a virus in an individual comprising administering an effective amount of a drug nanosuspension combined with a surfactant, wherein the drug nanosuspension combined with the surfactant is delivered to the individual's lungs. Preferably, the drug is a nanosuspension delivered to the individual's lungs through inhalation.
Absstract of: US2025127882A1
A nucleic acid-lipid nanoparticle is provided, which comprises: a nucleic acid molecule and a lipid mixture. The lipid mixture comprises: an ionizable amino lipid present in an amount of 20 mol % to 60 mol %; a phospholipid present in an amount of 5 mol % to 20 mol %; cholesterol present in an amount of 25 mol % to 60 mol %; and a PEGylated lipid present in an amount of 0.2 mol % to 6 mol %. In addition, methods using the aforesaid nucleic acid-lipid nanoparticle are also provided.
Absstract of: US2025127919A1
The present disclosure relates to methods of loading an EV with a payload. In some aspects, the payload and the EV are mixed at a specific loading condition (e.g., at the disclosed salt concentrations, loading temperature, loading duration, payload feed concentration, and/or EV feed concentration), such that the amount of the payload that is associated with the exterior surface of the EV is increased. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.
Absstract of: US2025127868A1
The present disclosure relates to lipid nanoparticles comprising a lysophosphatidylcholine (LPC) compound and at least one further lipid, and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells. The present disclosure also relates to compositions comprising lipid nanoparticles comprising a LPC and at least on further lipid, in which the compositions comprise one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.
Absstract of: US2025129386A1
The present disclosure discloses a nanoparticle vector for RNA self-delivery and a preparation method therefor and use thereof. The nanoparticle vector includes: a β-cyclodextrin-RNA conjugate, an adamantane-ligand conjugate, and a cationic polymer, wherein the adamantane-ligand conjugate is formed by conjugating adamantane with a ligand molecule through polyethylene glycol. Through a host-guest interaction between β-cyclodextrin and an adamantane molecule, the nanoparticle vector can realize the modular conjugation of a delivered RNA molecule and the ligand molecule, and realize the self-delivery of RNA. The polyethylene glycol molecule can avoid the recognition and phagocytosis of immune cells before the vector enters target cells, and β-cyclodextrin can realize the escape of intracellular nucleosome. The nanoparticle vector delivers RNA to cells in a targeted manner, and is degraded in vivo via endocytosis, releasing RNA molecules to inhibit expression of genes of interest, and play a role in repairing cartilage and bone tissue in situ.
Absstract of: US2025127728A1
Ionizable cationic lipids, methods for synthesizing the same, intermediates useful in synthesis of the ionizable cationic lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is an LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.
Absstract of: US2025127727A1
Provided are ionizable lipids containing a piperazine moiety, as well as lipid nanoparticles that can be formed using the ionizable lipids for use in delivering nucleic acids and other therapeutic agents to specific cell types.
Absstract of: US2025127719A1
The present disclosure relates to ionizable lipidoid compounds comprising an anisamide moiety, and lipid nanoparticles (LNPs) comprising the same. In certain embodiments, the LNP selectively binds to at least one sigma receptor. In certain embodiments, the LNP specifically targets a cell of interest (e.g., a cell expressing a sigma receptor, fibroblast, cancer cell, stromal cell, and epithelial cell, inter alia). In another aspect, the present disclosure provides methods for in vivo delivery of therapeutic agents to treat, prevent, and/or ameliorate diseases and/or disorders, including but not limited to fibrosis and cancer.
Absstract of: WO2025084940A1
The invention relate to a compound of the general formula presented in the description of the invention for use in the treatment or prevention of diseases associated with vascular endothelial dysfunction, wherein it is provided in nanocapsules having a diameter of no more than 1 pm, containing a lipophilic core and a hydrophilic shell, wherein the nanocapsules are intended for oral administration.
Absstract of: WO2025085881A1
Nanoemulsions (NEs) and nanocapsules (NCs), are disclosed that include nanoparticles that can readily diffuse/distribute throughout the nervous system and that can deliver a therapeutic agent thereto. Methods of making and using the same also are disclosed, especially for treating diseases and/or disorders in which delivery of a therapeutic agent to and/or throughout the nervous system are needed.
Absstract of: WO2025083617A1
The present disclosure includes a composition including a) one or more nucleic acid constructs, wherein the one or more nucleic acid constructs encode: at least one of Replicase 68 (Rep68) and Replicase 78 (Rep78); and at least one protein of viral origin having nucleic acid replication and/or transgene amplification promotion activity, and b) nucleic acid construct comprising a coding region encoding at least one gene of interest (GOI) and at least one inverted terminal repeat (ITR) sequence on each side of the GOI, and methods of making and using the composition.
Absstract of: WO2025083423A1
The invention relates to a self-assembling conjugate molecule, the conjugate molecule comprising a hydrophobic polymer covalently bound to human serum albumin (HSA) only at residue Cys34; or a hydrophobic polymer covalently bound to a non-human serum albumin protein only at an equivalent residue to Cys34 of HSA; and associated compositions, uses and methods of treatment.
Absstract of: CN117567535A
The present application relates to bio-orthogonal compositions. The present disclosure provides bioorthogonal compositions for delivering agents in a subject. The disclosure also provides methods of producing these compositions and methods of using these compositions.
Absstract of: PH12021500045A1
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The ionizable amine lipids disclosed herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions.
Absstract of: MX2021009485A
Disclosed herein are methods for treating osteoarthritis may be a one-step arthroscopic procedure and may include detaching synovial mesenchymal stem cells (MSCs) from the synovium using a brush device; covering articular cartilage in an affected joint with a scaffold; and placing concentrated MSC exosomes into the affected joint to stimulate differentiation of synovial MSCs into articular cartilage cells.
Absstract of: WO2023245177A2
This disclosure relates to compositions and methods for treating lung disorders, including, for example, Acute Respiratory Distress Syndrome (ARDS), Ventilator-Induced Lung Injury (VILI), Acute lung injury (ALI), and other acute and chronic lung disorders.
Absstract of: WO2023245176A1
This disclosure relates to compositions and methods for treating lung disorders, including, for example, pulmonary fibrosis, and other fibrotic disorders. Thioredoxin domain-containing 5 (TXNDC5) is significantly increased in fibrotic lungs from human PF patients. Therefore, a targeted nanoparticle comprising an inhibitor of TXNDC5 was developed, which may have potential to treat pulmonary fibrosis.
Absstract of: AU2023290551A1
The present invention is within the technical field of pain-relief and relates to a pharmaceutical composition comprising at least one anesthetic agent selected from the group consisting of ropivacaine, bupivacaine, etidocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, articaine, dibucaine, levobupivacaine, prilocaine, benzocaine, chloroprocaine, cocaine, procaine, proparacaine, tetracaine and any pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof; at least one alkanolamine selected from the group consisting of triethanolamine, tripropanolamine and trimethanolamine; water; and optionally a pharmaceutically acceptable diluent, carrier and/or excipient. The present disclosure furthermore relates to the use of the composition for providing pain-relief, a method of treatment, a method of producing said pharmaceutical composition as well as a carbon quantum dot formed from components of the pharmaceutical composition.
Absstract of: AU2023290273A1
Chimeric antigen receptor (CAR)-expressing neutrophils loaded with nanoparticles comprising a drug; and a method of treating cancer or other disorders in a subject comprising administering to the subject a therapeutically effective amount of the CAR-expressing neutrophils.
Absstract of: WO2023244803A1
This application relates in part to nanoparticles comprising a tobamovirus and nanoparticles comprising a tobamovirus and beta-cyclodextrin (β-CD or BCD). This application also relates in part to nanoparticles comprising tobamovirus and one or more active ingredients (AIs) that are non-covalently conjugated to the tobamovirus. The application also provides methods of making and methods of using such nanoparticles as well as compositions comprising the disclosed nanoparticles.
Absstract of: MX2025000643A
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
Absstract of: AU2023290692A1
Provided herein include compositions, methods and systems for delivery of CRISPR/Cas-mediated gene editing systems using lipid nanoparticles (LNP) to trabecular meshwork cells. Methods, compositions and systems for treating glaucoma are also provided herein, which involve reducing the expression of myocilin (
Absstract of: WO2023242843A1
The technology generally concerns selective modulation of only a peripheral CB 1R by using a CB 1R antagonist contained in a peripherally restricted delivery system.
Absstract of: AU2023295550A1
The present disclosure provides a method of enhancing an immune response in a subject in need thereof, including administering an effective amount of an antigen with an immune modulator to the subject, wherein the immune modulator is a quaternary immunomodulatory nanoparticle (QIN). The present disclosure also provides the use of the QIN in the manufacture of a chimeric nanoparticle, a pharmaceutical composition and a medicament for treating a subject suffering from a cancer or virus infection.
Absstract of: AU2023244571A1
The present disclosure provides a lipid nanoparticle for extrahepatic delivery of mRNA, the lipid nanoparticle comprising: (i) mRNA cargo; (ii) a phosphatidylcholine lipid content of from 30 mol% to 70 mol%; (iii) a ionizable, cationic lipid content of from 5 mol% to 50 mol%; (iv) a sterol selected from cholesterol or a derivative thereof; and (v) a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0.5 mol% to 5 mol. Further provided is a lipid nanoparticle comprising encapsulated mRNA and 20 to 70 mol% of a phosphatidylcholine lipid, an ionizable lipid; and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticle exhibiting at least a 10% increase in gene expression of the mRNA in vivo as measured in one or more extrahepatic organs or tissues. Further provided are methods of administration of such lipid nanoparticles.
Absstract of: WO2023192503A1
Lipid nanoparticle formulations with cell type specific transfection activity and capable of producing Th1 and/or Th2 response in vivo and their use for plasmid DNA or mRNA delivery is disclosed.
Absstract of: CN118922178A
The present disclosure provides a lipid nanoparticle comprising: a nucleic acid load molecule; sterols or derivatives thereof present in high levels; a neutral lipid; lipid can be ionized; and a hydrophilic polymer-lipid conjugate present in a content of between 0.5 and 3 mol%, wherein each mol% content is relative to the total lipid present in the lipid nanoparticles.
Absstract of: WO2023199036A1
The present application relates to a nucleic acid molecule comprising a promoter operably linked to a nucleic acid sequence encoding Myocyte Enhancer Factor 2C (MEF2C), or a functional variant thereof, wherein the promoter is for expression of MEF2C in macroglia. Also provided are vectors, compositions, products, methods, cells, medical uses and methods of treatment.
Absstract of: MX2024012237A
Disclosed herein are compositions comprising siRNAs capable of downregulating Cell Death-Inducing DFF45-like Effector Protein B (<i>CIDEB</i>) gene expression or a variant thereof. Also disclosed herein are methods of using such compositions in the treatment of a liver disease or injury, such as fatty liver disease (FLD), non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
Absstract of: CN119857150A
本发明提供了一种治疗肝细胞癌的核酸药物制剂及其制备方法和应用，属于核酸药物技术领域。本发明提供了一种核酸递送载体，包括中性胞苷脂材DNCA、胱氨酸骨架阳离子脂材CLD和辅助脂材1,2‑二硬脂酰基‑sn‑甘油‑3‑磷酸乙醇胺‑聚乙二醇DSPE‑PEG按特定比例复配得到。本发明还提供了一种治疗肝细胞癌的核酸药物，包括核酸递送载体、包裹在所述核酸递送载体内靶向IGF1RmRNA的siRNA和细胞转染液。所述核酸药物可高效靶向小鼠肝细胞皮下瘤部位，显著抑制肿瘤生长，且无肝肾毒性。本发明技术方案为抗该肝细胞癌的siRNA药物在临床的广泛应用奠定了基础。
Absstract of: CN119857110A
本发明提供一种肿瘤微环境响应型级联生成活性氧的纳米平台及其制备方法，该纳米平台包括FeOOH纳米纺锤体，所述FeOOH纳米纺锤体的外层包覆有四硫键掺入的树枝状介孔有机硅纳米粒子(DMOS NPs)，形成纳米颗粒DMOS@FeOOH。本发明的纳米平台能够在肿瘤组织中通过级联反应高效生成活性氧(ROS)，并实现对肿瘤细胞的选择性杀伤，具有较高的特异性、良好的治疗效果和较低的对正常组织的副作用，是一种具有广阔应用前景的肿瘤治疗策略。
Absstract of: CN119857085A
本发明提供了一种靶向治疗黄褐斑的siRNA脂质纳米颗粒及其制备方法和应用，属于生物医药技术领域。本发明提供了一种治疗黄褐斑的LNP‑siRNAs，包括靶向抑制黑色素形成关键分子的siRNAs。本发明筛选出有效的siRNA序列，在细胞中进行了验证，而后将有明显抑制作用的siRNAs包装成LNP‑siRNAs，评估LNP‑siRNAs的包装质量，以及将LNP‑siRNAs用于细胞和动物，评估其对黑色素的抑制效应。本发明包装成的LNP‑siRNAs后用于黑色素细胞和动物皮肤，发现其能有效抑制黑色素的形成，可作为筛选并制作临床治疗黄褐斑的潜在药物。
Absstract of: CN119857120A
本发明提供了一种石萝藦提取物纳米粒、制备方法及应用，属于生物医药技术领域。纳米粒由囊心填充物、载体材料、表面活性剂、乳化剂和水组成；所述囊心填充物为石萝藦提取物；所述载体材料为聚乙二醇‑聚乳酸。配比如下：L‑LA、PEG和辛酸亚锡的摩尔比为100:1:1制得聚乙二醇‑聚乳酸(PEG‑PLLA)，PEG‑PLLA与PC重量比为1:3制得PC@PEG‑PLLA纳米颗粒。PC@PEG‑PLLA NPs的平均粒径为(113.1±2.5)nm，PDI为(0.173±0.020)，电势为(‑46.7±1.9)mV，同时具有良好的稳定性。作为治疗自身免疫性肝炎(AIH)的药物具有较高的价值。
Absstract of: MX2025000397A
Self-amplifying RNA (saRNA) molecules encoding an influenza virus antigen and methods of use thereof are disclosed herein.
Absstract of: WO2025084940A1
The invention relate to a compound of the general formula presented in the description of the invention for use in the treatment or prevention of diseases associated with vascular endothelial dysfunction, wherein it is provided in nanocapsules having a diameter of no more than 1 pm, containing a lipophilic core and a hydrophilic shell, wherein the nanocapsules are intended for oral administration.
Absstract of: CN119841854A
本发明涉及药物技术领域，具体提供了一种活性氧响应的紫杉醇前药，具有式Ⅰ或式Ⅱ所示结构。本发明针对紫杉醇疏水聚集问题，对紫杉醇药物进行了改性，改性后的紫杉醇药物水溶性大大增强，并获得了自组装性能，在水溶液中可以进行自组装得到纳米粒子，所述纳米粒子具有超高的载药量和载药效率，并且可以特异性响应肿瘤微环境中高浓度的活性氧，既能改善传统紫杉醇纳米制剂载药量的不足，又能在肿瘤位置响应释放紫杉醇，有利于减少药物用量，降低毒副作用，对提升患者预后，延长患者生存期具有重要意义。
Absstract of: CN119838009A
本发明公开了一种肿瘤免疫微环境调控型光激活铁死亡纳米粒及其制备方法和应用，涉及生物医药技术领域。该制备方法包括以下步骤：将白蛋白和铁蛋白溶于水中，调节pH为碱性后加入光敏剂和硫辛酸，混合后再加入溶剂，进行混合反应，之后加入交联剂，继续反应后，经过离心和干燥处理，得到所述肿瘤免疫微环境调控型光激活铁死亡纳米粒。该肿瘤免疫微环境调控型光激活铁死亡纳米粒通过诱导肿瘤细胞铁死亡、激活树突状细胞和调控M2型肿瘤相关巨噬细胞的M1型极化来逆转肿瘤免疫抑制微环境，进而增强肿瘤免疫治疗效果。
Absstract of: TW202412846A
The present invention addresses the problem of providing a novel copolymer that can be used for a drug delivery technique. The present invention relates to a copolymer obtained by binding a target-affinity molecule to a copolymer X comprising structural units represented by formula (A), (B), and (C). In the formulae, R1, R2, and R3 are the same or different and each represent a hydrogen atom or a C1-3 alkyl group; R4 represents a C1-3 alkyl group; R5 represents a hydrogen atom, a C1-18 alkyl group, an optionally substituted, 3- to 8-membered cycloalkyl group, an adamantyl group, an optionally substituted C6-18 aryl group, or an optionally substituted, 5- to 10-membered heteroaryl group; X1, X2, and X3 are the same or different and each represent an oxygen atom, a sulfur atom, or N-R7; R6 represents a hydrogen atom, a leaving group, or a linker; R7 represents a hydrogen atom or a C1-3 alkyl group; m is an integer of 1-100; and n is an integer of 0-3..
Absstract of: CN119841848A
本发明公开了一种新型AIE光热剂及其制备方法与应用。本发明的AIE光热剂的结构式如下所示，其发光性能和光热转化性能优越，可用于制备肿瘤诊断试剂或肿瘤治疗药物。本发明制备的负载AIE光热剂和STING激动剂的仿生纳米粒子能够实现药物至肿瘤组织高效递送，基于AIE分子的多模态成像能力对肿瘤进行靶向示踪，其光热效应能够增强肿瘤细胞ICD和DC细胞的STING通路激活，增增强抗肿瘤免疫治疗，最终抑制远端肿瘤生长，肿瘤复发和再转移。本发明材料制备工艺简单，成本较低，适用于规模生产和临床医疗使用。#imgabs0#
Absstract of: CN119841930A
本发明公开了一种抗原MNA及其应用和制备的疫苗、药物，属于生物医药技术领域。本发明发现并设计的新型肿瘤新抗原（MNA）具有强免疫原性，能够有效激活T细胞免疫反应；且仅在肿瘤细胞中表达，不受中枢免疫耐受的影响，能够精准靶向肿瘤细胞，减少对正常组织的损伤。且利用circRNA作为新抗原MNA的表达载体，稳定性高，高效表达，诱导强烈的新抗原特异性T细胞反应，无需佐剂。本发明为肿瘤新抗原疫苗的开发和个性化免疫治疗提供了新的思路，有助于推广至更多的高突变负荷肿瘤类型，具有广阔的临床应用前景。
Absstract of: CN119837842A
本发明提供一种基于超氧化物歧化酶的纳米透皮递送系统，为小分子活性成分‑超氧化物歧化酶‑聚合物壳层的胶囊复合结构，小分子活性成分负载在超氧化物歧化酶中，超氧化物歧化酶表面被聚合物壳层包覆，所述基于超氧化物歧化酶的活性成分透皮递送系统直径为20‑100nm，聚合物壳层厚度为7.5‑52.5nm。本发明递送系统中聚合物壳层为超氧化物歧化酶和具有抗氧化作用的小分子功能物质提供保护作用，所述胶囊复合结构为纳米凝胶的形式，纳米凝胶不仅促进其渗透深度，而且减轻了其对皮肤的刺激作用。本发明原料生物友好，制备方法简单，收率高，可以工业化大规模生产。
Absstract of: CN119837841A
本发明提供一种用于皮肤抗炎的蓝萼甲素纳米透皮递送系统，为蛋白‑蓝萼甲素‑聚合物壳层的胶囊复合结构，所述蛋白对皮肤有亲和作用，蓝萼甲素负载于蛋白中，聚合物层包覆在蛋白的表面，所述蓝萼甲素纳米透皮递送系统尺寸为30‑80nm，聚合物壳层厚度为10‑35nm。聚合物外壳表面性质可以根据透皮递送的深度需求进行调控，使得蛋白质突破皮肤屏障被高效递送至皮肤深处再将蓝萼甲素缓慢释放，靶向缓解皮肤炎症，解决蓝萼甲素治疗皮肤炎症因透皮效果不理想而治疗效果低下的缺陷。
Absstract of: CN119837843A
本发明属于生物医药技术领域，公开一种用于治疗阿尔兹海默症的双药纳米颗粒及其制备方法和应用，将Aβ抑制剂通过化学键连接在两亲性聚合物上，连有Aβ抑制剂的两亲性聚合物和STING抑制剂混合，在超声下缓慢的滴加到水中，超声、过滤取上层，得到双药纳米颗粒，本发明制备的双药纳米颗粒具有较好的生物相容性、稳定性，能穿过血脑屏障并同时对Aβ和小胶质细胞STING通路作用，解聚Aβ并促进Aβ清除、抑制小胶质细胞STING通路激活，减少释放炎症因子损伤神经元；能明显减少脑部沉积的Aβ和显著抑制脑内小胶质细胞STING通路的激活，明显的改善了小鼠记忆能力、空间识别能力，改善了脑部炎性微环境。
Absstract of: WO2025080206A1
This disclosure relates to methods of promoting infiltration of a nanoparticle-based anti-cancer drug into a solid tumor of a subject using mechanical stimulation. Devices for performing such a method are also disclosed. In one embodiment, the mechanical stimulation is a compressive force applied to the tumor or to a tissue surrounding the tumor, or to a tissue in the vicinity of the tumor. In another embodiment, the device comprises an actuator capable of providing mechanical stimulation to the solid tumor or to the tissue in the vicinity of the solid tumor when positioned at a proximate location from the tumor on an external skin surface.
Absstract of: WO2025080572A1
A compound having the structure (I), (II), (III), or (IV) is provided: (I), (II), (III), (IV) ) where in these structures, (I), (II), (III), and (IV), each R1 is independently selected from aliphatic alkyl C4-C100 groups optionally substituted with one or more of alkenyl, alkynyl, hydroxyl, amide, ester, and/or ether groups; R2 is selected from -OCH2CH2-p or (A); R3 is selected from Formula (V) and Formula (VI): (V, (VI). M+ is selected from an alkali metal ion, an alkaline earth metal ion, or a primary, secondary or tertiary ammonium ion; and m, p, and s are independently selected from integers from 1 to 120. The compound is useful as a liver asialoglycoprotein receptor-targeted therapeutic agent in the form of a lipid nanoparticle, a liposome or a micelle including a drug or oligonucleotide.
Absstract of: WO2025076771A1
The present invention belongs to the technical field of biology. Disclosed are an ionizable lipid, a pharmaceutical composition comprising same, and the use thereof. Provided in the present invention is a compound as represented by formula (I), or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt or deuterated compound thereof, which serves as an ionizable lipid, overcoming the technical defect whereby other ionizable lipid compounds in the prior art are all mainly delivered to the liver for the expression of antigen proteins and cannot be delivered to the spleen. The compound represented by formula (I) provided by the present invention has the characteristics of good spleen-organ-targeting property, high delivery efficiency, etc. The compound represented by formula (I) provided by the present invention can be used for the preparation of liposomes, lipid nanoparticles, drug carriers or complexes, and used for the delivery of nucleic acid drugs.
Absstract of: WO2025076625A1
Provided is a glutamic or glutaric acid-based ionizable lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof. The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 20 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 10 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. In some embodiments, the ionizable lipid compound is a glutamic acid-based ionizable lipid compound.
Absstract of: WO2025077898A1
An effective and safe composition comprises an anionic gold-polydopamine core-shell nanoworm as an alternative gene carrier for bypassing the bottleneck of endosomal entrapment. The nanoworm can be used in methods of delivering therapeutic oligonucleotides to a subject. A polydopamine shell supports the surface adsorption of nucleic acids. The anionic nucleic acid-encased nanoworm can then enter cells without transfection agents and activate the ClC3 H +/Cl - exchanger in late endosomes to mediate vesicular accumulation of H + and Cl -, which causes membrane rupture, and finally escape to cytosol without cell-penetrating peptides or mechanical stimuli. The nanoworm can be further used for programming cellular responses, i. e., primary macrophage polarization and stem cell differentiation, for the treatment of diseases, such as kidney fibrosis and acute liver injury.
Absstract of: WO2025081192A1
The disclosure concerns oral formulations that enable delivery of therapeutic agents that are sensitive to stomach pH and/or have reduced ability to be absorbed. In one aspect, the oral formulation comprises: (a) phenyl boric acid (PBA)-functionalized chitosan grafted with branched polyethyleneimine (PEI) and (b) a therapeutic agent, wherein the therapeutic agent is encapsulated by the PB A- functionalized chitosan grafted with a branched PEI. In other aspects, the oral formulation comprises: (a) chitosan grafted with branched polyethyleneimine (PEI), (b) a therapeutic agent, wherein the therapeutic agent is encapsulated by the chitosan grafted with a branched PEI, and optionally (c) a eukaryotic cell membrane fragment. The disclosure also concerns methods of making and administering such oral formulations.
Absstract of: WO2025081185A1
Disclosed herein are methods for delaying the onset of type I diabetes and preventing nosocomial infections by administering PEG-b-PPS nanocarriers loaded with rapamycin. This invention aims to reduce the frequency of visits to a transfusion clinic, reduce the costs of treatments, and reduce adverse side effects, without reducing the effects of the islet transplant. This is accomplished by the use of a nanocarrier which targets treatment to the desired location.
Absstract of: WO2025077933A1
The present invention relates to the technical field of microencapsulation of natural products, and specifically relates to a water-soluble ginger oleoresin microcapsule, and a preparation method therefor and the use thereof. In the present invention, by using modified starch, plant polysaccharide substances, etc., as wall materials and ginger oleoresin as the core material, a ginger oleoresin microcapsule product is obtained by means of the processes of molecular coating of the ginger oleoresin, emulsification, high-pressure homogenization, leaving to stand at a constant temperature, drying, etc. The product has the characteristics of a high gingerol content, good water solubility, and low spiciness in the form of a solution; moreover, the product has good stability in an acid solution environment, can meet the requirements of high stability, no precipitation, low spiciness and good thermal sensation in a low-pH environment, and is applicable to the fields of food products, beverages, health-care food products, medicines, cosmetics, etc.
Absstract of: WO2025077899A1
Provided are a lyophilized preparation of a lipid nanoparticle (LNP) containing a nucleic acid, and a preparation method therefor and a use thereof. A lyophilized preparation of an LNP containing a nucleic acid is provided, and the lyophilized preparation comprises: i) an LNP containing a nucleic acid; and ii) a buffer reagent containing a lyoprotectant. The prepared nucleic acid-LNP lyophilized preparation has a uniform sample particle size, a small polydispersity index, high entrapment efficiency, and high RNA integrity after reconstitution. Moreover, the nucleic acid is prevented from leaking from the nanoparticle, and a lyophilization preservation method is further provided, so that the nanoparticle can exist in a stable form under refrigeration conditions.
Absstract of: WO2025077709A1
A preparation method for a micro-vehicle formed by enveloping siRNA-loaded polypeptide dendrimer nanogel with a cell membrane of engineered MSCs, and the use of same. The method comprises: using lentivirus-mediated gene transfection technology for constructing MSCs that highly express CXCR4 and PSGL-1; using cytokinin B for stimulating a cell to generate vesicles, and then performing centrifugation to collect the vesicles; by means of the electrostatic attraction between polypeptide dendrimer nanoparticles and siRNAs, attaching the siRNAs of IL-6 and HIF-1α into the polypeptide dendrimer nanoparticles; and by means of using a membrane extruder, enveloping the siRNA-loaded polypeptide dendrimer nanogel with the cell membrane. The prepared micro-vehicle exhibits a good property of aggregating at inflammatory blood vessel sites and a targeting function for joint cavities with rheumatoid arthritis. In addition, the loaded siRNAs can inhibit the expressions of IL-6 and HIF-1α in the joint cavities and inhibit the cell migration and angiogenesis. The micro-vehicle targeting inflammation sites has the advantages of excellent biocompatibility, ideal siRNA loading ratio, good inflammation targeting function, etc.
Absstract of: WO2025081013A1
The disclosures provides compositions comprising nanoparticles and a junction opener protein; and nanoparticles comprising one or more bioactive agents and a junction opener protein that is conjugated to the surface of the nanoparticles. Various bioactive agents are described, such as squalene, squalane, and dehydroisosqualene, among others. Various nanoparticle compositions are provided, including lipid carriers comprising a hydrophobic core. Methods for treating a subject with cancer by administering the compositions provided herein are also described.
Absstract of: WO2025077347A1
The present invention relates to a multimeric fusion protein nano-vector and the use thereof, and belongs to the technical field of genetic vector materials. The present invention designs a fusion protein containing a cell-penetrating peptide, a linker peptide and a human ferritin light chain, and optionally further containing a T cell or B cell antigenic-determinant antigenic peptide. The fusion protein constructed by the present invention can be used as a nano drug vector to target to dendritic cells, thus improving the transfection efficiency of dendritic cells. The fusion protein nucleic acid vector prepared by the present invention has greatly improved biocompatibility, still has cell viability of 80% or above at high concentrations, and has good safety, and therefore has a wide application prospect in the field of pharmacy.
Absstract of: WO2025080854A1
The present disclosure provides lipid nanoparticles for delivery of a payload (e.g., messenger RNA (mRNA)) to the heart. For example, lipid nanoparticle comprises an acid-degradable polyethylene glycol (PEG)-lipid (ADP) having molecular weight in the range of 1000 to 4500 Da. In some embodiments, the acid-degradable polyethylene glycol (PEG)-lipid is present in a mole percentage of about 1% to about 25% of the total lipids. The disclosure also encompasses methods for delivery of messenger RNA (mRNA) for transfection of cells, methods of treatment, as well as kits thereof.
Absstract of: WO2025080867A1
Provided herein are ionizable cationic lipids and lipid nanoparticle compositions comprising a lipid component comprising the same. Also, provided herein is a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering an effective amount of the lipid nanoparticle composition disclosed herein.
Absstract of: WO2025080649A1
Disclosed herein are POEGMA-based block copolymers that have phase transition and self-assembly properties. The disclosed block copolymers can take advantage of these properties to form particles that can effectively encapsulate and deliver drugs. An example block copolymer includes a first block that includes POEGMA with ethylene glycol side chains of 2 monomers, 3 monomers, or combinations of both; and a second block that includes POEGMA with ethylene glycol side chains of 1 monomer, 2 monomers, or combinations of both. Also disclosed herein are compositions that include the block copolymers, methods of treating a disease or disorder, and methods of delivering a drug.
Absstract of: WO2025080770A1
Methods are disclosed for increasing retinal ganglion cell (RGC) survival and/or RGC axon regeneration and/or optic nerve survival and/or optic never regeneration in a subject in need thereof. These methods include locally administering to an eye of the subject a therapeutically effective amount of (a) isolated nanovesicles derived from an extracellular matrix and (b) a statin or a pharmaceutically acceptable salt thereof. Combination therapy is also disclosed for use in increasing RGC survival and/or RGC axon regeneration and/or or optic nerve survival and/or optic nerve regeneration in a subject. Disclosed is therapeutically effective amount of (a) isolated nanovesicles derived from an extracellular matrix and (b) a statin or a pharmaceutically acceptable salt thereof, for use in increasing RGC survival, RGC axon regeneration and/or optic nerve survival and/or optic never regeneration in a subject in need thereof in a subject, wherein the isolated nanovesicles and the statin are formulated for ophthalmic administration.
Absstract of: WO2025080869A1
Drug delivery nanoparticle compositions and methods for the treatment of a cancer are provided that can be used individually or in combination. These compositions and methods include: (1) exogenous vaccination using neoantigens or tumor-associated antigens to potentiate an anti-tumor immune response; (2) nanoparticle-based drug delivery targeting the liver, aimed at reprogramming the hepatic immune environment to reduce or eliminate tumor antigen tolerance, thereby enhancing the immune system's ability to combat metastatic cancer; and (3) expansion of the liver metastasis treatment platform to target tumor-associated lymphoid structures, supporting the immune response at the primary tumor site. Any of these methods may be optionally combined with chemo-immunotherapy for enhanced efficacy.
Absstract of: WO2025080555A1
In one aspect, the present disclosure relates to certain ionizable lipid compounds and methods of preparation thereof. In another aspect, the present disclosure relates to lipid nanoparticles (LNPs) comprising certain ionizable lipid compounds of the present disclosure and methods of use thereof.
Absstract of: WO2025079599A1
The present invention addresses the problem of providing: a carrier that allows selective delivery thereof to a cell at a subset level, which cannot be realized by a conventional technique; and a method for producing said carrier. The present invention relates to: a carrier for realizing selective delivery thereof to a target cell having a plurality of target receptors on a surface thereof, wherein the carrier has individual ligands that respectively bind to the plurality of receptors, and is incorporated into target cells having all of the plurality of receptors, but not into cells that do not have at least one of the plurality of receptors; and a method for producing said carrier.
Absstract of: WO2025079114A1
A self-nano emulsifying drug formulation for cholecalciferol by a method of spontaneous emulsification and spray drying, the self-nano 5 emulsifying drug formulation for cholecalciferol comprising of one active ingredient cholecalciferol, powder substrates, oil phases, surfactants and co-surfactants, wherein, the active ingredient having a loading capacity range from 100 IU/g to 10,00,000 IU/g and has an increased rate of dissolution, increased rate of permeability and increased bioavailability of the at least one active ingredient, wherein, the method for adsorption of the self-nano emulsifying drug on the substrate to obtain a powder formulation is spontaneous emulsification and spray drying method (SESDM) where the homogenous mixture of self-nano emulsifying drug and the aqueous dispersion of solid substrate is prepared and atomized into fine droplets and kept in a drying chamber for rapid evaporation of liquid to form a powder formulation.
Absstract of: WO2025081106A2
Disclosed herein are protein-based compositions and conjugates thereof that can take advantage of beneficial delivery properties to improve vaccine efficacy. An example protein-based composition includes an albumin-binding nanobody and a peptide antigen domain. An example conjugate includes the protein-based composition attached to a drug through a linker. Also disclosed are methods of making and using the protein-based compositions and conjugates thereof.
Absstract of: MX2024000327A
The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.
Absstract of: WO2025081194A2
Antigen-presenting nanoparticles and methods of engineering CAR T cells and treating and/or preventing cancer using the same.
Absstract of: MX2024012714A
Methods and compositions for cellular rejuvenation of immune cells, such as T cells, are provided. Cellular rejuvenation can be achieved by exposure, such as transient exposure, of immune cells to mRNAs encoding reprogramming factors. Compositions comprising such rejuvenated immune cells, including rejuvenated T cells, and uses of the rejuvenated immune cells in treating certain diseases and/or disorders, such as cancer and immune disorders, are also provided
Absstract of: CN119032086A
The present invention relates to novel sulfide-containing ionizable lipids. When the lipid nanoparticles are generated, the ionizable lipid according to the present invention enables the drug to be efficiently encapsulated in the lipid nanoparticles and enables the drug to be stably delivered into the body by electrostatically interacting with the anionic drug, thereby improving the bioavailability of the drug. Therefore, the method can be effectively applied to the related fields such as lipid nanoparticle mediated gene therapy and the like.
Absstract of: AU2023254203A1
The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction with an LNP-encapsulated CRISPR/Cas9 gene editing system.
Absstract of: US2025115715A1
Provided are a polymer compound and a composition for nucleic acid delivery comprising the same, wherein the polymer compound has a high binding affinity to nucleic acids and effectively protects nucleic acids from nucleases, thereby improving the nucleic acid delivery effect and stability.
Absstract of: US2025120928A1
The present disclosure provides polymer-drug conjugates comprising suberoylanilide hydroxamic acid (SAHA), derivatives thereof, and salts thereof. The disclosure further provides nanoparticles comprising the polymer-drug conjugate. The disclosure provides methods of treating a disease or disorder in a subject by administering the conjugate or a plurality of nanoparticles comprising the conjugate to the subject. In some embodiments, the disease or disorder is sepsis, septic shock, hemorrhagic shock, or poly-trauma.
Absstract of: US2025120912A1
Synergistic nanomedicine delivering topoisomerase I toxin (SN-38) and inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for enhanced treatment of colorectal cancer
Absstract of: US2025120914A1
The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.
Absstract of: US2025120904A1
A method and apparatus for the targeted delivery of chemotherapy to a surgical cavity, consisting of a triggered nanoparticle encapsulating a therapeutic agent and an energy delivery device that applied trigger energy to the surgical cavity. Following surgical removal of a cancerous tumor, the nanoparticle is administered, and the energy delivery device applies trigger energy to the surgical cavity and proximal tissue. The goal is the delivery of a therapeutic drug dose to cancerous and precancerous cells remaining after surgery, to prevent local tumor recurrence.
Absstract of: US2025122247A1
The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
Absstract of: US2025121052A1
Disclosed herein are vaccine compositions that include SARS-CoV-2 MHC epitope-encoding cassettes and/or full-length SARS-CoV-2 proteins. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.
Absstract of: US2025121098A1
The present invention provides nanoparticles or conjugates comprising at least one ligand that selectively targets major facilitator superfamily domain-containing protein-2a (MFSD2A). In various embodiments, the nanoparticles or conjugates of the invention target at least one cell comprising MFSD2A (e.g., endothelial cells of blood brain barrier). In some embodiments, the nanoparticles or conjugates of the invention cross the blood brain barrier and/or blood retinal barrier. In other aspects, the present invention relates to methods for in vivo delivery of diagnostic and/or therapeutic agents to a brain. In other aspects, the present invention relates to methods of preventing or treating a neurological or cognitive disease or disorder using the nanoparticles or conjugates of the invention.
Absstract of: US2025121043A1
The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
Absstract of: US2025120997A1
Disclosed herein is a composition including a nucleoside-modified mRNA encapsulated in a lipid nanoparticle wherein the nucleoside-modified mRNA encodes IL10, IL-6, MIP1a, GDNF (glial cell line-derived neurotrophic factor), or a combination thereof. A method of treated spinal cord injury is also described.
Absstract of: US2025120916A1
The instant disclosure teaches a highly efficient cellulose-based nanoadsorbent that can capture more than 6000 mg of doxorubicin (DOX), one of the most widely used chemotherapy drugs, per gram of the adsorbent at physiological conditions. Such drug capture capacity is more than 3200% higher than other nanoadsorbents, such as DNA-based platforms. The disclosure teaches how anionic hairy cellulose nanocrystals, also known as electrosterically stabilized nanocrystalline cellulose (ENCC), bind to positively charged drugs in human serum and capture DOX immediately without imposing any cytotoxicity and hemolytic effects. The disclosure further elucidates how ENCC provides a remarkable platform for biodetoxification at varying pH, ionic strength, ion type, and protein concentration. These discoveries pave the way for the next generation in vitro and in vivo drug capture additives and devices.
Absstract of: US2025120913A1
A pharmaceutical composition of Quercetin nanosuspension comprising Quercetin dihydrate, about 0.1% w/w to 10% w/w of Poloxamer, about 0.1% w/w to 10% w/w of polyvinyl pyrrolidone, and about 0.1% w/w to 10% w/w of polyethylene glycol. A method for preparing Quercetin nanosuspension, comprising the steps of dissolving polyvinyl pyrrolidone, Poloxamer, and polyethylene glycol in purified water, adding Quercetin to the above solution, subjecting the resulting mixture to bead milling to form Quercetin nanocrystals or nanosuspension.
Absstract of: US2025121079A1
This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.
Absstract of: AU2023357320A1
The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g., but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g., in combination with a chemotherapeutic agent). The present disclosure further provides RNA backbones containing specific sequences upstream and/or downstream from the coding sequence.
Absstract of: WO2025077836A1
Provided herein is novel ionizable cationic lipid compound that can be assembled with other helper lipids, such as phospholipids, structural lipids, and polymer conjugated lipids capable of reducing aggregation, to form lipid nanoparticles for delivery of therapeutic RNA both in vitro and in vivo. These compounds contain a thiourea group in the linker between the lipid group and the head group (-NRc-C(S)-NRd-).
Absstract of: WO2025080945A1
The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.
Absstract of: WO2025081002A1
Novel ionizable lipids, compositions, and methods of using the novel lipids and compositions are disclosed. Lipid nanoparticle compositions include novel lipids as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticle compositions further including biologically active agents such as mRNA are useful in the delivery of therapeutics, diagnostics and/or prophylactics to cells or organs.
Nº publicación: WO2025080209A1 17/04/2025
Applicant:
AGENCY FOR SCIENCE TECH AND RESEARCH [SG]
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Absstract of: WO2025080209A1
There is provided a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein AR comprises a unit from a poly(amino acid); R1 and R2 are each independently a hydrophobic group; R3, R4, and R5 are each independently H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R7 is -H or -C(=O)R8, wherein R8 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy; m ≥ 1; and n ≥ 1.
BOPI
Electronic site
